Foster Wayne 4

4 · Atea Pharmaceuticals, Inc. · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 4, 2026

Atea (AVIR) EVP Wayne Foster Receives 108,000 RSUs, Withholds 12,132 Shares

What Happened

Wayne Foster, Executive Vice President and Chief Accounting Officer of Atea Pharmaceuticals (AVIR), had restricted stock units (RSUs) and related derivative awards vest/convert on Jan 31, 2026. The filing shows a grant/award or conversion totaling 108,000 RSU-type shares and an additional 41,333 shares from derivative conversion recorded as acquired. To cover tax withholding, 12,132 shares were surrendered at $4.24 per share for $51,440. Other derivative conversion entries show 33,333 and 8,000 shares as disposed (reported at $0), consistent with net settlement/withholding activity. Overall the reported activity results in a net increase of 95,868 shares based on the reported acquired and disposed line items.

Key Details

Transaction date: January 31, 2026; Form 4 filed February 3, 2026 (timely — within the SEC’s two-business-day window).
Tax withholding: 12,132 shares surrendered at $4.24/share = $51,440 to cover tax liability (code F).
Reported entries: 108,000 shares (A: award/grant, RSU-type), 41,333 shares acquired via conversion (M), and disposals of 33,333 and 8,000 shares (M), plus the 12,132-share tax withholding (F).
Shares owned after transaction: not specified in the provided excerpt of the filing.
Relevant footnotes: F1 clarifies each RSU converts to one share; F2 notes an original 100,000 RSU grant vested in full as of Jan 31, 2026; F3 notes performance RSUs vested upon satisfying performance criteria on Jan 31, 2026; F4 describes an option’s future monthly vesting schedule starting Jan 31, 2026.

Context

These were not open-market purchases or sales in the usual sense: the activity reflects RSU vesting/conversion and internal withholding to satisfy tax obligations (common, administrative actions rather than an opportunistic buy/sell signal).
The $0.00 amounts on some derivative lines reflect conversion/settlement mechanics (not a market sale at zero value). The only cash value reported in the excerpt is the tax withholding ($51,440).
For retail investors: awards and vesting are routine compensation events; purchases are generally more informative about bullish insider sentiment, while vesting/withholding is typically administrative.

Form 4

Period: 2026-01-31

EVP, Chief Accounting Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-01-31+41,333→ 91,461 total
Tax Payment
Common Stock
2026-01-31$4.24/sh−12,132$51,440→ 79,329 total
Exercise/Conversion
Restricted Stock Units
[F1][F2]
2026-01-31−33,333→ 0 total
→ Common Stock (33,333 underlying)
Exercise/Conversion
Restricted Stock Units
[F1][F3]
2026-01-31−8,000→ 0 total
→ Common Stock (8,000 underlying)
Award
Stock Option (Right to Buy)
[F4]
2026-01-31+108,000→ 108,000 total
Exercise: $4.24Exp: 2036-01-30→ Common Stock (108,000 underlying)

Footnotes (4)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
[F2]The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.
[F3]Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.
[F4]The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.

Signature

/s/ Andrea Corcoran, as Attorney-in-Fact for Wayne Foster|2026-02-03

1 file